In a regulatory filing, Scholar Rock ( SRRK) CEO Jay Backstrom disclosed the sale of 18,372 common shares of the company on February 18 at a price of $36.829 per share. Published first on TheFly – the ...

Shares of Scholar Rock Holding Co. (NASDAQ:SRRK – Get Free Report) have been assigned a consensus rating of “Buy” from the ...

CAMBRIDGE, MA—Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 9,039 shares of the company's common stock. The shares were sold at an average price of $44. ...

Following this transaction, Parlavecchio retains ownership of 145,554 shares, which includes 52,046 shares of common stock and 93,508 RSUs. Following this transaction, Parlavecchio retains ...

CAMBRIDGE, Mass., February 10, 2025--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy ...

Ted Myles, COO & CFO at Scholar Rock, will remain with the Company through mid-March, and then serve as a Senior Advisor for six months, during the leadership transition. “I am delighted to have ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

KBC Group NV purchased a new stake in Scholar Rock Holding Co. (NASDAQ:SRRK – Free Report) during the fourth quarter, HoldingsChannel.com reports. The firm purchased 3,020 shares of the company’s ...